Welcome to our dedicated page for Theravance Biopharma SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma, Inc. reported that it has completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study. This trial is evaluating a treatment in patients with symptomatic neurogenic orthostatic hypotension caused by multiple system atrophy.
The company described the study as pivotal and noted that all information related to this milestone is provided in a press release furnished as an exhibit. That press release is supplied for informational purposes and is not deemed filed under securities laws.
Rick E. Winningham, identified as both a Director and the Chief Executive Officer of Theravance Biopharma, reported a Form 4 transaction dated 08/20/2025. The filing discloses that 15,394 ordinary shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units; the withholding was executed with the issuer and did not involve an open market sale. The report shows 1,717,786 shares beneficially owned directly after the transaction, plus 13,500 shares held as custodian and 92,567 shares held by trust, all listed as indirect holdings. The stated price per share associated with the withheld shares is $13.39. The form was signed by an attorney-in-fact on 08/22/2025.
Sawaf Aziz, SVP & Chief Financial Officer of Theravance Biopharma (TBPH), reported a disposition of 9,368 ordinary shares on 08/20/2025 at an effective price of $13.39 per share. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, and the withholding was not an open-market sale. After the withholding, Mr. Aziz beneficially owns 355,422 ordinary shares, held directly.
Theravance Biopharma insider report: Miller Aine, SVP, Development & Head of IRE Office and an officer of Theravance Biopharma (TBPH), had 6,989 ordinary shares withheld on 08/20/2025 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. The withholding was executed with the issuer and was not an open-market sale. After the transaction, the reporting person beneficially owned 208,001 shares. The per-share price for the withheld shares is reported as $13.39. The Form 4 was signed by an attorney-in-fact on 08/22/2025.
Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma, reported a transaction on Form 4. On 08/20/2025 he disposed of 9,762 ordinary shares at an average price of $13.39 per share. The filing states the shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units; the withholding was executed with the issuer and was not an open-market sale. After the transaction he beneficially owned 374,306 shares (direct). The Form 4 is signed 08/22/2025.
Rhonda Farnum, Senior Vice President, Commercial & Medical Affairs at Theravance Biopharma (TBPH), reported a Form 4 disclosing a routine share withholding on 08/20/2025 to satisfy tax obligations from the vesting of previously granted restricted stock units. The filing shows 9,096 ordinary shares were withheld at an effective price of $13.39 per share; no open-market sale occurred. After the withholding, Farnum beneficially owned 317,822 shares of TBPH. The Form 4 is filed individually and signed by an attorney-in-fact on behalf of the reporting person.
Theravance Biopharma, Inc. announced that its subsidiaries and partners Mylan Ireland Limited and Viatris Specialty L.P. have entered into a Settlement Agreement with Cipla Limited and Cipla USA, Inc. covering YUPELRI® (revefenacin) inhalation solution patents. The agreement resolves ongoing Hatch-Waxman patent litigation related to Cipla’s abbreviated new drug application for a generic YUPELRI® product in the United States.
Under the Settlement Agreement, Theravance and Mylan granted Cipla a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market Cipla’s generic version of YUPELRI® in the United States on or after the Licensed Launch Date of April 23, 2039, subject to customary exceptions. The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and separate patent litigation remains pending against another ANDA filer, Mankind Pharma Ltd. and certain affiliates.
Theravance Biopharma reported a profitable second quarter driven by a large one-time gain from the sale of TRELEGY royalties. The company recognized a net gain of $75.137 million on the sale and reported net income of $54.835 million for the three months ended June 30, 2025. Total revenues were $26.195 million for the quarter, including $18.695 million from the Viatris collaboration and a $7.5 million China regulatory milestone recognized as licensing revenue.
Liquidity strengthened materially: cash, cash equivalents, and restricted cash rose to $282.8 million and total assets increased to $426.0 million. Total shareholders' equity was $224.8 million, reducing the accumulated deficit to $924.3 million. The company retains potential remaining milestone receipts from Royalty Pharma of up to $150.0 million and remains eligible for additional Viatris milestones and China-region royalties. Legal proceedings related to ANDA filings and patent litigation are ongoing, with several settlements announced but some cases still pending.
Theravance Biopharma notified investors that it has issued a press release and will hold a conference call presenting its financial results for the quarter ended June 30, 2025 and a business update.
The materials supporting the call are being furnished as Exhibit 99.1 (press release) and Exhibit 99.2 (slide deck). The filing states these exhibits are furnished and not filed, which limits certain statutory liabilities associated with filed disclosures.